Canagliflozin vs NAD+
A side-by-side research comparison of Canagliflozin and NAD+ across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Canagliflozin | NAD+ |
|---|---|---|
| Full name | Canagliflozin (SGLT2 Inhibitor) | Nicotinamide Adenine Dinucleotide (NAD+ / NMN / NR) |
| Category | Anti-Aging | Anti-Aging |
| Status | FDA-approved drug | Research compound |
| Mechanism | Blocks the sodium-glucose cotransporter 2 in the kidney, causing excess glucose to be excreted in urine. This lowers blood glucose independent of insulin, reduces blood pressure and weight, and produces cardio-renal protective effects. | NAD+ serves as cofactor for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38. Declining NAD+ impairs mitochondrial function and epigenetic maintenance. Restoration reactivates longevity pathways. |
| Molecular weight | 444.52 Da | 663.4 Da |
| Half-life | ~11-13 hours | 1-4 hours (IV), 4-8h (oral precursors) |
| Bioavailability | ~65% oral | 100% (IV), variable (oral 5-30%) |
| Typical dose | 100-300 mg per day | 250-500mg IV or 500-1000mg NMN oral |
| Frequency | Once daily | Weekly (IV) or Daily (oral) |
| Route | Oral tablet | IV infusion or Oral (precursors) |
Canagliflozin reported benefits
- Insulin-independent glucose lowering
- Cardiovascular protection
- Kidney protection
- Blood pressure reduction
- Weight loss
- Longevity signal (ITP data)
NAD+ reported benefits
- Restored cellular energy
- Enhanced DNA repair
- Sirtuin activation
- Improved mitochondrial function
- Cognitive clarity
- Anti-aging
Related comparisons
Research and educational reference only. Not medical advice.